Three-Dimensional Quantitative Assessment of Ablation Margins Based on Registration of Pre- and Post-Procedural MRI and Distance Map by Tani, Soichiro et al.
Three-Dimensional Quantitative
Assessment of Ablation Margins Based
on Registration of Pre- and Post-
Procedural MRI and Distance Map
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Tani, Soichiro, Servet Tatli, Nobuhiko Hata, Xavier Garcia-Rojas,
Olutayo I. Olubiyi, Stuart G. Silverman, and Junichi Tokuda.
2016. “Three-Dimensional Quantitative Assessment of Ablation
Margins Based on Registration of Pre- and Post-Procedural MRI
and Distance Map.” International Journal of Computer Assisted
Radiology and Surgery 11 (6) (April 2): 1133–1142. doi:10.1007/
s11548-016-1398-z.
Published Version 10.1007/s11548-016-1398-z
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33953712
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
Three-dimensional quantitative assessment of ablation margins 
based on registration of pre- and post-procedural MRI and 
distance map
Soichiro Tani,
Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School 75 
Francis Street, Boston, MA 02115, USA, Tel.: +1-617-732-7389, Fax: +1-617-582-6033. 
Biomedical Innovation Center and Department of Surgery, Shiga University of Medical Science 
Seta Tsukinowa-Cho, Otsu, Shiga, 520-2192, Japan
Servet Tatli,
Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School 75 
Francis Street, Boston, MA 02115, USA, Tel.: +1-617-732-7389, Fax: +1-617-582-6033
Nobuhiko Hata,
Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School 75 
Francis Street, Boston, MA 02115, USA, Tel.: +1-617-732-7389, Fax: +1-617-582-6033
Xavier Garcia-Rojas,
Texas Medical Center, 2450 Holcombe Blvd. Suite X, Houston, TX 77021, USA
Olutayo I. Olubiyi,
Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School 75 
Francis Street, Boston, MA 02115, USA, Tel.: +1-617-732-7389, Fax: +1-617-582-6033
Stuart G. Silverman, and
Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School 75 
Francis Street, Boston, MA 02115, USA, Tel.: +1-617-732-7389, Fax: +1-617-582-6033
Junichi Tokuda
Department of Radiology, Brigham and Women’s Hospital and Harvard Medical School 75 
Francis Street, Boston, MA 02115, USA, Tel.: +1-617-732-7389, Fax: +1-617-582-6033
Soichiro Tani: stani@partners.org; Servet Tatli: statli@partners.org; Nobuhiko Hata: nhata@partners.org; Olutayo I. 
Olubiyi: oolubiyi@partners.org; Stuart G. Silverman: sgsilverman@partners.org; Junichi Tokuda: jtokuda@partners.org
Abstract
Purpose—Contrast-enhanced MR images are widely used to confirm the adequacy of ablation 
margin after liver ablation for early prediction of local recurrence. However, quantitative 
assessment of the ablation margin by comparing pre- and post-procedural images remains 
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challenging. We developed and tested a novel method for three-dimensional quantitative 
assessment of ablation margin based on non-rigid image registration and 3D distance map.
Methods—Our method was tested with pre- and post-procedural MR images acquired in 21 
patients who underwent image-guided percutaneous liver ablation. The two images were co-
registered using non-rigid intensity-based registration. After the tumor and ablation volumes were 
segmented, target volume coverage, percent of tumor coverage, and Dice Similarity Coefficient 
were calculated as metrics representing overall adequacy of ablation. In addition, 3D distance map 
around the tumor was computed and superimposed on the ablation volume to identify the area 
with insufficient margins. For patients with local recurrences, the follow-up images were 
registered to the post-procedural image. Three-D minimum distance between the recurrence and 
the areas with insufficient margins were quantified.
Results—The percent tumor coverage for all non-recurrent cases was 100%. Five cases had 
tumor recurrences, and the 3D distance map revealed insufficient tumor coverage or a 0-millimeter 
margin. It also showed that two recurrences were remote to the insufficient margin.
Conclusions—Non-rigid registration and 3D distance map allows us to quantitatively evaluate 
the adequacy of the ablation margin after percutaneous liver ablation. The method may be useful 
to predict local recurrences immediately following ablation procedure.
Keywords
Liver ablation; MRI; Image-guided intervention; ablation margin; image registration
1 Introduction
Image-guided percutaneous thermal ablations, such as radiofrequency ablation (RFA) 
[8,5,48,40], cryoablation [8,5,46,39], and microwave coagulation therapy (MCT) 
[8,5,27,43,22], are promising alternatives to surgical resection for liver tumor treatment. 
There has been a strong demand for those thermal ablations; while the liver is the dominant 
metastatic site for gastrointestinal primary tumors [14], and the origin of the sixth most 
common cancer worldwide [47], curative treatment options for liver tumors are currently 
limited to surgical resection and thermal ablations. Thermal ablations are particularly 
important for those who are not eligible for surgical resection. Thermal ablations allow 
ablating tumor under image guidance without major incisions, and thus provide low 
morbidity rates with less complications and hospitalization [8,9]. Although thermal ablation 
methods are effective, particularly for tumors less than 3 cm in diameter [13], recurrences 
occur. Achievement of an adequate ablation margin is an important common denominator of 
complete ablation and therefore the success of the therapy [32,18,44]. Adequacy of the 
ablation margin is assessed by post-procedural contrast-enhanced computed tomography 
(CT) or magnetic resonance imaging (MRI) [4,19,20,29]. However, the tumor is often 
obscured on the post-procedural images making it difficult to evaluate the ablation margin 
using a post-procedural image alone. For this reason, radiologists typically estimate the 
ablation margin by comparing the pre- and post-procedural images side by side using 
anatomical landmarks and mental registration. This practice is cumbersome and may 
underestimate or overestimate the ablation margins within a three-dimensional (3D) volume.
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Alternatively, pre- and post-procedural images can be registered to one another using image 
registration techniques [17,50,2,12,35]. Image registration techniques can correct the 
misalignment between the two images, allowing radiologists to compare the ablation volume 
and the tumor directly; hence, this may improve the prediction of inadequate ablation 
coverage and may allow for more prompt retreatment in the hope of achieving improved 
local tumor control. Particularly, non-rigid registration techniques can compensate 
deformation of the anatomy between the two exams, and offer better registration accuracy 
than conventional rigid registration techniques [10,36]. Kim et al successfully used a non-
rigid registration technique for the evaluation of ablation margins in their clinical study [17]; 
the deformable registration allowed them not only to examine overall ablation margin, but 
also to localize the thinnest margin with respect to the tumor, and correlate it with local 
recurrences. However, their approach to the localization of the thinnest margin relies on 
radiologists’ visual assessment of the margin and encoding using a spherical coordinated 
system fitted to the ablation volume. While this was a novel way to assess the ablation 
margins, it can still be objective especially when the ablation volume is not a complete 
sphere.
In this study, we developed a new method to quantitatively assess the ablation margin and 
correlate it with local recurrence. The feasibility of the method was evaluated using pre- and 
post-procedural images, and follow-up images of patients who underwent image-guided 
percutaneous ablations. Our method generates a 3D distance map around the tumor, and 
overlays it on the ablation volume to visualize the distribution of the ablation margin on the 
surface of the ablation volume after registering the pre- and post-procedural images. 
Furthermore, the method can calculate the distance between the area with a positive or the 
thinnest margin and the local recurrence to correlate them.
2 Methods
2.1 Patient Selection
The study protocol has been reviewed and approved by the institutional review board, and 
was HIPAA compliant. A total of 208 hepatic percutaneous ablation procedures were 
performed between January 1, 2008 and December 31, 2012. Patients were not limited to 
certain image guidance modalities, thermal ablation modalities, or tumor histologies; the 
ablations were performed under CT, MR, or positron emission tomography (PET)/CT 
guidance using MCT, RFA, or cryoablation techniques.
We used inclusion criteria shown in Fig. 1 to avoid any confounding factor that might cause 
local recurrences and ensure that the patient underwent necessary follow-up exams.
After all exclusions, a total of 21 hepatic tumors (mean tumor volume 8.0 cm3, range 0.4–
40.2 cm3; mean greatest tumor diameter 2.0 cm, range 0.9–4.1 cm3) in 19 patients (mean 
age 60, range 42–84; 8 female, 14 male) were enrolled. The characteristics of target lesions 
including primary origin and their sizes, and ablation modalities used to treat them are 
shown in Table 1.
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2.2 Pre- and Post-Procedural Imaging and Follow-up
All pre-procedure MRI exams were performed within 30 days (mean 11.5 days, range 1–27 
days) before the procedure using one of the following 1.5T or 3T MRI scanners with a 
phased-array body coil: MAGNETOM Aera, MAGNE-TOM Trio, or MAGNETOM Verio 
(Siemens AG, Munich, Germany); or Signa EXCITE 1.5T, Signa HDx 1.5T, Signa HDx 3T, 
Signa HDxt 1.5T, or Signa HDxt 3T (GE Healthcare, Waukshesha, WI). CE-MR images 
were acquired using a T1-weighted 3D gradient-echo sequence before and 30, 60, and 90 
seconds after intravenous administration of 0.1 mmol/kg of gadopentetate dimeglumine 
(Magnevist, Bayer HealthCare Pharmaceuticals, Berlin, Germany). The post-procedure MR 
images were also acquired in the same manner, within 72 hours following the procedure. 
The patients were followed up with CE-MR or CT images at regular intervals, at least for a 
year. We defined local recurrence as a post-procedural development of tumor adjacent to or 
within ablation area [33,32]. Among the 21 patients, recurrences were found in five patients.
2.3 Ablation
Patients underwent one of the following procedures: cryoablations (n=12) performed using 
argon-gas-based cryotherapy applicators (IceRods and Ice-Spheres, Galil Medical Ltd., 
Yokneam, Israel) with two 15-minute freezing cycles separated by a 10 minute passive thaw; 
radiofrequency ablations (n=7) performed using an RF generator (Cool-tip system, 
Covidien, Mansfield, MA) at 120 watts with impedance control for 12 minutes; microwave 
ablation (n=2) performed using a needle-like applicator (AMICA, HS Medical, Boca Raton, 
FL) with 80 watts for 15 minutes.
2.4 Non-Rigid Registration and Segmentation of Tumor and Ablation Zone
The pre-procedural CE-MR and follow-up images were registered to the post-procedural 
images. We used a non-rigid B-Spline registration technique, which has been tested 
extensively in our group and provided reasonable registration accuracy in several clinical 
applications [10,37,11]. The B-Spline registration can correct for deformation of the liver, 
and thus it can provide better alignment than the affine registration technique alone (4.1 mm 
vs 11.04 mm; p < 0.05)[10]. The pre- and post-procedural CE-MR images of the 21 cases 
were loaded onto open-source image-processing and visualization software (3D Slicer 
version 4; http://www.slicer.org/) on a Linux workstation. Before applying non-rigid 
registration, the intensity bias of the MR images within the liver was corrected using the 
N4ITK Bias Correction module in 3D Slicer with a grid of 5×5×5. A region of interest 
(ROI) was defined manually on the liver for the bias correction. Registration was performed 
using the General Registration module in 3D Slicer 4. The following steps were used: 
alignment of the center of the region of interest (ROI), rigid registration, affine registration, 
and non-rigid B-Spline registration. We used the aforementioned ROI of the liver for 
registration. The B-Spline grid was set to be 6 per direction. We used a hierarchical 
registration approach[11], where the degree-of-freedom (DOF) of registration transform was 
gradually increased through the hierarchical process. We included rigid (6-DOF), affine (12-
DOF), and B-spline (125-DOF) in this process. The registration accuracy was evaluated 
using target registration error (TRE). The TRE was calculated based on five corresponding 
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anatomical landmarks manually selected on the pre-procedural, post-procedural, and follow-
up images.
Once the images were registered, the tumor, and ablation zone were segmented manually on 
the pre- and post-procedural images by an abdominal surgeon (S. Tani), and were reviewed 
and revised by a board-certified radiologist (S. Tatli). Tumors were identified as areas of 
abnormal enhancement or washout on the pre-procedural CE-MRI. Ablation zone was 
identified by new unenhancing area encompassing the tumor on the post-procedural CE-MR 
images.
2.5 Assessment of Ablation Margin
The adequacy of ablation margin was evaluated using a volumetric approach used in our 
previous study [45], and a distance -based approach newly introduced in this study.
Volumetric Approach—The following three metrics were calculated: 1) Percent of target 
volume coverage defined as the percentage of ablation zone within the target volume, which 
combines the volume of the tumor and the desired margin; 2) Percent of tumor volume 
coverage defined as the percentage of ablation zone within the tumor; and 3) Dice Similarity 
Coefficient (DSC) that measures the agreement between the target volume and the ablation 
zone. The percent of target volume coverage, percent of tumor volume coverage, and DSC 
can be formulated as (% target volume coverage) = (a/b) ×100, (% tumor volume coverage) 
= (a/c) × 100, and (DSC) = (2a/(2a + b + d) respectively, where a is the volume common to 
the tumor and the ablation zone, b is the volume of the target, c is the volume of the tumor, 
and d is the volume of the ablation zone. The target volume was defined as the tumor and a 
10-mm volumetric margin extending in all directions perpendicular to the manually 
segmented tumor surface [45], which was calculated using the ErodeDilateLabel module in 
3D Slicer software.
Distance-Based Approach—The area with insufficient ablation margin (positive margin 
or thinnest margin) was identified using a 3D distance map superimposed on the 3D surface 
model of the ablation volume. The distance map is a volumetric image computed for a given 
region (i.e. tumor); each voxel represents the minimum Euclidian distance from the voxel to 
the region (Fig. 2). By computing a distance map of the tumor region and superimposing it 
on the surface of the ablation zone, one can estimate the minimum distance from each point 
on the ablation volume surface to the tumor surface. Therefore, the superimposed distance 
map represents the distribution of the thickness of ablation margin (Fig. 2). We defined the 
area with a distance equal to zero or positive margin as an area of insufficient margin. The 
minimum distance value was recorded as a thinnest margin. We used an algorithm to 
compute the Euclidian distance map proposed by Maurer et al [28] available in the Insight 
Segmentation and Registration Toolkit (http://itk.org/).
2.6 Assessment of Local Recurrence
To assess the local recurrence, the follow-up image was registered to the post-procedural 
image using the aforementioned non-rigid registration. The recurrent tumor was manually 
segmented in the same manner as the tumor segmentation on the pre-procedural image. The 
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3D distance between the local recurrence and the area with insufficient ablation margin 
(positive margin or thinnest margin) was measured by the following steps: 1) the 3D 
distance map from the area of insufficient margins were calculated; 2) the 3D distance map 
was overlaid on the segmentation of recurrent tumors; and 3) the minimum distance between 
the area of insufficient ablation and the local recurrence was calculated by finding the 
minimum value within the recurrent tumor on the distance map.
2.7 Statistical Analysis
DSC, percentage of target volume coverage, percentage of tumor coverage, tumor volume, 
and tumor diameter were compared between outcome groups using a two-sample t test. 
Complete tumor coverage of ablation zone was compared between the two outcome groups 
via Fishers exact test. Only two-sided p-values at preset with a significant (alpha) level of 
0.05 were reported. All statistical analysis was performed in STATA Version 11.2 
(StataCorp, College Station, TX).
3 Results
Representative results of image registration and visual assessment of pre- and post-
procedural images and follow-up images are shown in Fig. 3. The target registration errors 
(TRE) were 2.23 ± 0.95 mm for pre- and post-procedural images, and 2.40 ± 0.35 mm for 
post-procedural and follow-up images based on landmarks manually defined in the liver 
regions. The result of ablation margin assessment with volumetric approach is shown in 
Table 2. Out of the 21 procedures, local recurrences were found in five cases. For the cases 
with recurrence, the pre-procedural tumor volume and the largest diameter were 
significantly higher than those for the cases without recurrence (21.7 ± 14.0 cm3 vs 2.5 ± 2.2 
cm3 (p < 0.001) and 3.5 ± 0.6 cm vs 1.5 ± 0.9 cm (p < 0.001) respectively) (Table 3). The 
mean percent of tumor coverage for the cases with local recurrence was significantly lower 
than that of the other cases (99.7±0.3% vs 100.0 ± 0.3% (p < 0.001)). The DSC for the cases 
with local recurrence was higher than that for the cases without local recurrences (66.9 
± 8.0% vs 52.6± 8.4% (p = 0.004)). Of the 21 procedures, none of them had 100% target 
volume coverage (with 10 mm margin) by their ablation zones. Four procedures resulted in 
less than 100% coverage, and local recurrences were found in the all four cases. However, 
there was one recurrence with 100% tumor coverage. A branch of the portal vein with a 
diameter of 4.0 mm was adjacent to the tumor in this case.
The evaluation using the distance map showed that the thinnest margins for the five cases 
with recurrence were all zero, while the other cases without recurrence had thinnest margins 
of more than 1 mm. Distribution of ablation margin on the ablation volume surface and the 
relationship between the area of insufficient margin and the local recurrence are shown in 
Fig. 4. Three of five recurrences were found at the area of insufficient margin. One of the 
other two recurrent tumors was 2.7 cm away from the insufficient margin. The other 
recurrent case did not show the obvious positive margin, and the recurrent tumor was 2.7 cm 
away from the area of the insufficient margin.
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4 Discussion
In this study, we demonstrated the feasibility of our method for quantitative assessment of 
ablation margin using non-rigid registration technique and 3D distance map, and its potential 
to predict local recurrence. When insufficient tumor coverage was found with non-rigid 
registration, a local recurrence was highly likely. Although we applied a 10-mm margin for 
the target volume as suggested by previous studies [51,38,1,16], it is rare to be able to 
achieve it in all directions due to anatomical restriction, such as contiguous organs and large 
vessels [31]. The 3D distance map enabled even more detailed analysis of the ablation 
margin; the result showed that the all cases with the thinnest margin of zero led to 
recurrences. Margins less than 10 mm might be reasonable for percutaneous liver ablation 
[31,18,44,23]. Compared to the distance-based assessment, % tumor coverage did not 
predict local recurrences well. % tumor coverage does not change from its maximum value 
(100) unless there is a positive margin; hence % tumor coverage of 100 cannot distinguish 
the thickness of margins. This is particularly problematic when the tumor and ablation 
volumes are very close, because variability of segmentation of tumor and ablation volume 
can turn < 100 % tumor coverage to 100.
Among the cases with local recurrences, the distance map revealed that three of the five 
were at the areas of insufficient margins. In two cases, recurrences were not at the areas of 
insufficient margins (Cases 2 and 5). These discordant results are likely due to the fact that 
recurrences can occur secondary to other factors such as adjacent large blood vessels [31,25] 
rather than insufficient ablation margins. In fact, a large branch of the portal vein was 
adjacent to the tumor in Case 2, in which a recurrence occurred without obvious insufficient 
margins. Studies have revealed that large vessels contiguous to hepatic tumors are likely to 
be a risk factor of local recurrence after liver ablation [31,25,26], and this might have led to 
recurrence in this case. In addition, non-rigid registration may not correct for the 
deformation of the liver completely; the treatment and/or changes in disease condition can 
change the liver shape significantly, making it difficult to register the pre- and post-
procedural images and follow-up images. Local deformation of the liver due to shrinkage 
[41] and inflammatory response in the ablation area [5] and/or liver regeneration [42] may 
account for local recurrence distant from the insufficient ablation margin.
Blood vessels can cause insufficient ablation margins. Kim et al reported that blood vessels 
affected 50.5% (48/95 cases) of insufficient ablation margins [18]. In the representative case 
shown in Fig. 3, there was a right branch of portal vein on the inferior side, and a middle 
hepatic vein on the right side of the tumor. Since injuries of vessels had to be avoided, the 
tumor might have been insufficiently ablated near the hepatic vein.
Accurate registration is crucial for the distance-based ablation margin analysis. While our 
qualitative evaluation of registration by the clinicians were satisfactory, the TRE between the 
preprocedural, postprocedural, and follow-up images suggests that the registration error 
might not be ignorable. The slice thicknesses was not consistent in this study (2.0–4.0 mm) 
and larger thicknesses might have affected the registration error; using a smaller and 
consistent slice thickness could improve registration accuracy and hence reliability of result 
for the future prospective study.
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Because this preliminary study was focused on correlation between the metrics for ablation 
margins and local recurrence, we applied rigorous exclusion criteria to eliminate all possible 
factors that could potentially confound our correlation. We excluded cases with unclear 
boundary of ablated areas, because they could cause inaccurate margin assessment. 
Similarly, we excluded tumors adjacent to the liver capsules, because they made it difficult 
to evaluate margins beyond liver surface. We excluded lesions within 1cm from other lesions 
treated previously, because they led to overlapped ablation volumes that would make the 
borders of ablation volume invisible. Target volumes overlapped with prior treatment area 
were also excluded, because they could also lead to invisible borders of ablation volumes.
The proposed analysis could be performed in conjunction with the existing clinical work 
flow. We considered the following clinical work flow: a) pre-procedural contrast-enhanced 
MRI within 30 days prior to ablation (day −30); b) ablation procedure (day 0); c) post-
procedural contrast-enhanced MRI within 72hours following the treatment (day +1); d) 
ablation margin assessment when the physician is available (day +5); e) additional procedure 
is scheduled when insufficient ablation is identified; f) follow-up contrast-enhanced MRI 
done periodically after sufficient ablation (day 30 to 365). The assessment (step d) is the 
only step added to the regular clinical work flow; it can be performed offline, and typically 
requires only 10–15 minutes of manual tasks and 15 minutes of computation. Therefore, it 
would be feasible to perform the assessment in a clinical routine. The manual tasks include 
drawing of region of interest for liver registration (three to five minutes per liver), contouring 
of tumors and ablation volume (three to five minutes).
In our study, the average volume and the largest diameter of target tumors in recurrent cases 
were significantly larger than those of non-recurrent cases. Smaller tumor volume is 
considered important for curative treatment; complete ablation of a large tumor is often 
technically challenging and results in insufficient tumor coverage[48,31,15,21]. In fact, our 
quantitative margin assessment showed that ablation of large tumors resulted in insufficient 
margins (thinnest margin = 0 mm) in all 4/4. This result suggests that higher recurrence rates 
for large tumors might be associated with technical challenges to achieve complete ablation 
in this group. While the study did not assess sufficient number of samples, we believe that 
the proposed quantitative assessment method will help physicians determine if additional 
ablation procedure is necessary, and potentially reduce local recurrence after ablation of 
large tumors.
There are several limitations in our study. First, our sample size is limited due to our 
extensive exclusion criteria to be able to evaluate ablation margin accurately. Even though 
we reviewed 208 cases with different ablation modalities performed during the period of 5 
years, we could only identify 21 cases that were suitable for our study. In particular, the 
availability of pre-procedural contrast-enhanced MR significantly reduced the sample size. 
Therefore, a future prospective study is crucial to ensure that all subjects undergo necessary 
examination before and after the treatment, and collect data effectively. Second, the ablation 
techniques were not uniform; three different ablation techniques, and three different image 
guidance modalities were included in the study. Tissue viability at the edge of ablation 
volume detected on the post-procedural image may differ between the ablation techniques 
[7]. Origin or pathological character of tumors might also affect the local recurrence rate 
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because recurrence patterns are different between tumor types [14, 3,34], but we could not 
compare the recurrence rates between different origins or pathological characters due to the 
limited sample size. Further evaluation of the method with a larger cohort would help 
understand the effectiveness of our method in predicting the local recurrence. Such a cohort 
would also allow us to compare the proposed method to the qualitative evaluation by 
radiologists. Third, variability in the manual segmentation of tumor and ablation volume 
might have degraded the accuracy of margin assessment. In the future, automatic 
segmentation would improve the assessment time and repeatability. In particular, automatic 
segmention of tumor and ablation volume by comparing the baseline and hepatobiliary-
phase on Gd-EOB-DTPA-based contrast-enhanced MR images would be of our interest. The 
technique could also be useful for monitoring the progress of ablation in real-time during the 
procedure. For example, the technique could be combined with intraprocedural non-rigid 
image registration for intraprocedure margin assessment [10, 37,49], MR thermometry for 
microwave ablation monitoring[30], MR-based ice ball monitoring for MRI-guided 
cryoablations[24]. In addition, the method could potentially integrated with other real-time 
imaging modalities such as contrast-enhanced ultrasound [52,6].
In conclusion, non-rigid registration and the 3D distance map allows us to quantitatively 
evaluate the adequacy of ablation margin after percutaneous liver ablation. This technique 
may be used to predict local recurrences at an early point in time even immediately 
following an ablation procedure and improve patient care.
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Fig. 1. 
Flowchart of inclusion criteria. The top box demonstrates the number of patients who 
underwent percutaneous liver ablation between January 1, 2008 and December 31, 2012.
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Fig. 2. 
Schematic 2D representation of ablation margin assessment using a distance map is shown. 
A distance map, which contains the minimum distances from the tumor region to each pixel, 
is calculated (left), and then superimposed on the ablation zone (right). The values in the 
pixels at the boundary of ablation zone represent the minimum distances from the tumor 
surface, hence these pixel values represent the thickness of ablation margin. The pixel with 
the minimum value represents the point of thinnest margin. In our analysis, a 3D distance 
map with a pixel size of 1 × 1 × 1 mm was used.
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Fig. 3. 
Co-registered pre-procedural, post-procedural, and follow-up CE-MR images show tumor, 
ablation volume, and recurrence respectively (Case 14). The orange and white dotted line 
superimposed on the follow-up image represents the locations of the tumor and the ablation 
zone. The recurrence indicated by the arrows is observed at the area with positive ablation 
margin.
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Fig. 4. 
Three-dimensional color maps of distance map between the original tumor and ablation zone 
are rendered on the surface of ablation zone for the cases with local recurrences. The red 
areas represent insufficient ablation margin. The 3D models of original (upper) and recurrent 
(lower) tumors are superimposed. The red areas represent ablation margins with a thickness 
close to zero.
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Table 1
Characteristics of 21 cases that met the inclusion criteria including the origin of malignancy for primary and 
metastatic tumors (Malignancy Origin) and the diameters of tumors. The primary origin of the hepatic 
malignancies included gastrointestinal stromal tumors (n=2), hepatocellular carcinoma (n=3), colorectal 
carcinoma (n=9), esophageal carcinoma (n=2), uterine sarcoma (n=1), carcinoid (n=1), thymoma (n=1), renal 
cell carcinoma (n=1), and endometrial carcinoma (n=1).
Case Ablation Modality Malignancy Origin Tumor Diameter (cm)
1 Cryo Colon 1.0
2 Cryo Esophagus 3.2
3 RFA GIST 2.1
4 Cryo HCC 1.3
5 Cryo HCC 4.0
6 RFA Esophagus 1.8
7 Cryo Uterine sarcoma 1.0
8 Cryo Colon 4.0
9 RFA Colon 2.8
10 RFA GIST 1.5
11 RFA HCC 1.4
12 RFA Carcinoid 1.7
13 Cryo Thymoma 1.1
14 MCT Colon 4.1
15 Cryo Colon 0.9
16 Cryo Colon 2.0
17 Cryo RCC 1.1
18 Cryo Colon 1.6
19 MCT Colon 2.7
20 RFA Endometrial Carcinoma 1.0
21 Cryo Colon 0.9
Cryo: cryoablation; RFA: radiofrequency ablation; MCT: microwave coagulation therapy; GIST: gastrointestinal stromal tumor; HCC: 
hepatocellular carcinoma.
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Table 3
Summary of tumor size, and ablation coverlage
Positive Negative p-value
Tumor diameter (cm) 3.5 ± 0.6 1.5 ± 0.9 < 0.001
Tumor volume (cm3) 21.7 ± 14.0 2.5 ± 2.2 < 0.001
Tumor coverage 99.6 ± 0.3 100.0 ± 0 < 0.001
Target coverage 81.9 ± 6.8 89.7 ± 11.1 0.15
Total tumor coverage 1 (of 5) 16 (of 16) 0.001
DSC 0.67 ± 0.08 0.52 ± 0.09 0.004
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